肠道菌群与结直肠癌关系的研究进展与展望
The Research Progress and Prospects of the Relationship between Gut Microbiota and Colorectal Cancer
DOI: 10.12677/acm.2025.152317, PDF,   
作者: 李 畅, 朱恬恬：包头医学院研究生院，内蒙古 包头；刘 聪, 澈 根：内蒙古医科大学研究生院，内蒙古 呼和浩特；东 丽*：内蒙古自治区人民医院肿瘤内科，内蒙古 呼和浩特
关键词: 结直肠癌；肠道菌群；益生菌；Colorectal Cancer； Gut Microbiota； Probiotics
摘要: 结直肠癌是全球范围内最常见的恶性肿瘤之一，其发生发展受到多种遗传和环境因素的影响。近年来，越来越多的研究表明，肠道菌群作为一种重要的环境因素，与结直肠癌的发病机制、临床特征和治疗效果密切相关。肠道菌群可以通过产生代谢物、基因毒素、致炎因子等方式，影响肠道上皮细胞、免疫细胞和肿瘤细胞的功能和相互作用，从而促进或抑制结直肠癌的发生和进展。本文综述了近年来关于肠道菌群与结直肠癌关系的研究进展，重点介绍了肠道菌群在结直肠癌发展及治疗中的作用，并对未来的研究方向和挑战进行了展望。
Abstract: Colorectal cancer is one of the most common malignant tumors worldwide, and its occurrence and development are influenced by various genetic and environmental factors. In recent years, an increasing number of studies have shown that the gut microbiota, as an important environmental factor, is closely related to the pathogenesis, clinical features, and treatment outcomes of colorectal cancer. The gut microbiota can affect the functions and interactions of intestinal epithelial cells, immune cells, and tumor cells through the production of metabolites, genotoxins, and pro-inflammatory factors, thereby promoting or inhibiting the occurrence and progression of colorectal cancer. This article reviews the research progress on the relationship between the gut microbiota and colorectal cancer in recent years, focusing on the role of the gut microbiota in the development and treatment of colorectal cancer, and looks forward to future research directions and challenges.
文章引用：李畅, 朱恬恬, 刘聪, 澈根, 东丽. 肠道菌群与结直肠癌关系的研究进展与展望[J]. 临床医学进展, 2025, 15(2): 69-75. https://doi.org/10.12677/acm.2025.152317

参考文献

[1] Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. [Google Scholar] [CrossRef] [PubMed]
[2] Cao, W., Chen, H., Yu, Y., Li, N. and Chen, W. (2021) Changing Profiles of Cancer Burden Worldwide and in China: A Secondary Analysis of the Global Cancer Statistics 2020. Chinese Medical Journal, 134, 783-791. [Google Scholar] [CrossRef] [PubMed]
[3] Xia, C., Dong, X., Li, H., Cao, M., Sun, D., He, S., et al. (2022) Cancer Statistics in China and United States, 2022: Profiles, Trends, and Determinants. Chinese Medical Journal, 135, 584-590. [Google Scholar] [CrossRef] [PubMed]
[4] Huang, Z. and Yang, M. (2022) Molecular Network of Colorectal Cancer and Current Therapeutic Options. Frontiers in Oncology, 12, Article 852927. [Google Scholar] [CrossRef] [PubMed]
[5] Hossain, M.S., Karuniawati, H., Jairoun, A.A., Urbi, Z., Ooi, D.J., John, A., et al. (2022) Colorectal Cancer: A Review of Carcinogenesis, Global Epidemiology, Current Challenges, Risk Factors, Preventive and Treatment Strategies. Cancers, 14, Article 1732. [Google Scholar] [CrossRef] [PubMed]
[6] Hanahan, D. (2022) Hallmarks of Cancer: New Dimensions. Cancer Discovery, 12, 31-46. [Google Scholar] [CrossRef] [PubMed]
[7] Vitali, F., Tortora, K., Di Paola, M., Bartolucci, G., Menicatti, M., de Filippo, C., et al. (2022) Intestinal Microbiota Profiles in a Genetic Model of Colon Tumorigenesis Correlates with Colon Cancer Biomarkers. Scientific Reports, 12, Article No. 1432. [Google Scholar] [CrossRef] [PubMed]
[8] Gomaa, E.Z. (2020) Human Gut Microbiota/microbiome in Health and Diseases: A Review. Antonie van Leeuwenhoek, 113, 2019-2040. [Google Scholar] [CrossRef] [PubMed]
[9] Brasiel, P.G.D.A., Dutra Luquetti, S.C.P., Peluzio, M.D.C.G., Novaes, R.D. and Gonçalves, R.V. (2020) Preclinical Evidence of Probiotics in Colorectal Carcinogenesis: A Systematic Review. Digestive Diseases and Sciences, 65, 3197-3210. [Google Scholar] [CrossRef] [PubMed]
[10] Gigola, G., Carriere, P., Novoa Díaz, M.B., Perdigon, G., Zwenger, A.O. and Gentili, C. (2021) Survival Effect of Probiotics in a Rat Model of Colorectal Cancer Treated with Capecitabine. World Journal of Gastrointestinal Oncology, 13, 1518-1531. [Google Scholar] [CrossRef] [PubMed]
[11] Wong, S.H. and Yu, J. (2019) Gut Microbiota in Colorectal Cancer: Mechanisms of Action and Clinical Applications. Nature Reviews Gastroenterology & Hepatology, 16, 690-704. [Google Scholar] [CrossRef] [PubMed]
[12] Zou, S., Fang, L. and Lee, M. (2017) Dysbiosis of Gut Microbiota in Promoting the Development of Colorectal Cancer. Gastroenterology Report, 6, 1-12. [Google Scholar] [CrossRef] [PubMed]
[13] Liu, W., Zhang, R., Shu, R., Yu, J., Li, H., Long, H., et al. (2020) Study of the Relationship between Microbiome and Colorectal Cancer Susceptibility Using 16SrRNA Sequencing. BioMed Research International, 2020, Article 7828392. [Google Scholar] [CrossRef] [PubMed]
[14] Kim, J. and Lee, H.K. (2022) Potential Role of the Gut Microbiome in Colorectal Cancer Progression. Frontiers in Immunology, 12, Article 807648. [Google Scholar] [CrossRef] [PubMed]
[15] Li, R., Shen, J. and Xu, Y. (2022) Fusobacterium Nucleatum and Colorectal Cancer. Infection and Drug Resistance, 15, 1115-1120. [Google Scholar] [CrossRef] [PubMed]
[16] Zaib, S., Hayat, A. and Khan, I. (2024) Probiotics and Their Beneficial Health Effects. Mini-Reviews in Medicinal Chemistry, 24, 110-125. [Google Scholar] [CrossRef] [PubMed]
[17] Faghfoori, Z., Faghfoori, M.H., Saber, A., Izadi, A. and Yari Khosroushahi, A. (2021) Anticancer Effects of Bifidobacteria on Colon Cancer Cell Lines. Cancer Cell International, 21, Article No. 258. [Google Scholar] [CrossRef] [PubMed]
[18] Wong, C.C. and Yu, J. (2023) Gut Microbiota in Colorectal Cancer Development and Therapy. Nature Reviews Clinical Oncology, 20, 429-452. [Google Scholar] [CrossRef] [PubMed]
[19] Saber, S., Abd El-Fattah, E.E., Yahya, G., Gobba, N.A., Maghmomeh, A.O., Khodir, A.E., et al. (2021) A Novel Combination Therapy Using Rosuvastatin and Lactobacillus Combats Dextran Sodium Sulfate-Induced Colitis in High-Fat Diet-Fed Rats by Targeting the TXNIP/NLRP3 Interaction and Influencing Gut Microbiome Composition. Pharmaceuticals, 14, Article 341. [Google Scholar] [CrossRef] [PubMed]
[20] Fu, C., Yang, Z., Yu, J. and Wei, M. (2021) The Interaction between Gut Microbiome and Anti-Tumor Drug Therapy. American Journal of Cancer Research, 11, 5812-5832.
[21] Džidić-Krivić, A., Kusturica, J., Sher, E.K., Selak, N., Osmančević, N., Karahmet Farhat, E., et al. (2023) Effects of Intestinal Flora on Pharmacokinetics and Pharmacodynamics of Drugs. Drug Metabolism Reviews, 55, 126-139. [Google Scholar] [CrossRef] [PubMed]
[22] LaCourse, K.D., Zepeda-Rivera, M., Kempchinsky, A.G., Baryiames, A., Minot, S.S., Johnston, C.D., et al. (2022) The Cancer Chemotherapeutic 5-Fluorouracil Is a Potent Fusobacterium Nucleatum Inhibitor and Its Activity Is Modified by Intratumoral Microbiota. Cell Reports, 41, Article 111625. [Google Scholar] [CrossRef] [PubMed]
[23] Siddik, Z.H. (2003) Cisplatin: Mode of Cytotoxic Action and Molecular Basis of Resistance. Oncogene, 22, 7265-7279. [Google Scholar] [CrossRef] [PubMed]
[24] Stojanovska, V., McQuade, R.M., Fraser, S., Prakash, M., Gondalia, S., Stavely, R., et al. (2018) Oxaliplatin-Induced Changes in Microbiota, TLR4+ Cells and Enhanced HMGB1 Expression in the Murine Colon. PLOS ONE, 13, e0198359. [Google Scholar] [CrossRef] [PubMed]
[25] Zhu, J. and Su, J. (2021) Alterations of the Gut Microbiome in Recurrent Malignant Gliomas Patients Received Bevacizumab and Temozolomide Combination Treatment and Temozolomide Monotherapy. Indian Journal of Microbiology, 62, 23-31. [Google Scholar] [CrossRef] [PubMed]
[26] Khan, S., Moore, R.J., Stanley, D. and Chousalkar, K.K. (2020) The Gut Microbiota of Laying Hens and Its Manipulation with Prebiotics and Probiotics to Enhance Gut Health and Food Safety. Applied and Environmental Microbiology, 86, e600-e620. [Google Scholar] [CrossRef] [PubMed]
[27] Lee, N., Son, S., Jeon, E.B., Jung, G.H., Lee, J. and Paik, H. (2015) The Prophylactic Effect of Probiotic Bacillus Polyfermenticus KU3 against Cancer Cells. Journal of Functional Foods, 14, 513-518. [Google Scholar] [CrossRef] 
[28] Consoli, M.L.D., da Silva, R.S., Nicoli, J.R., Bruña‐Romero, O., da Silva, R.G., de Vasconcelos Generoso, S., et al. (2015) Randomized Clinical Trial. Journal of Parenteral and Enteral Nutrition, 40, 1114-1121. [Google Scholar] [CrossRef] [PubMed]
[29] Torres-Maravilla, E., Boucard, A., Mohseni, A.H., Taghinezhad-S, S., Cortes-Perez, N.G. and Bermúdez-Humarán, L.G. (2021) Role of Gut Microbiota and Probiotics in Colorectal Cancer: Onset and Progression. Microorganisms, 9, Article 1021. [Google Scholar] [CrossRef] [PubMed]
[30] Fayol-Messaoudi, D., Berger, C.N., Coconnier-Polter, M., Liévin-Le Moal, V. and Servin, A.L. (2005) pH-, Lactic Acid-, and Non-Lactic Acid-Dependent Activities of Probiotic Lactobacilli against Salmonella enterica Serovar Typhimurium. Applied and Environmental Microbiology, 71, 6008-6013. [Google Scholar] [CrossRef] [PubMed]
[31] Mills, J.P., Rao, K. and Young, V.B. (2018) Probiotics for Prevention of Clostridium Difficile Infection. Current Opinion in Gastroenterology, 34, 3-10. [Google Scholar] [CrossRef] [PubMed]
[32] Jacouton, E., Chain, F., Sokol, H., Langella, P. and Bermúdez-Humarán, L.G. (2017) Probiotic Strain Lactobacillus Casei BL23 Prevents Colitis-Associated Colorectal Cancer. Frontiers in Immunology, 8, Article 1553. [Google Scholar] [CrossRef] [PubMed]
[33] Altonsy, M.O., Andrews, S.C. and Tuohy, K.M. (2010) Differential Induction of Apoptosis in Human Colonic Carcinoma Cells (Caco-2) by Atopobium, and Commensal, Probiotic and Enteropathogenic Bacteria: Mediation by the Mitochondrial Pathway. International Journal of Food Microbiology, 137, 190-203. [Google Scholar] [CrossRef] [PubMed]
[34] Shamekhi, S., Abdolalizadeh, J., Ostadrahimi, A., Mohammadi, S.A., Barzegari, A., Lotfi, H., et al. (2019) Apoptotic Effect of Saccharomyces Cerevisiae on Human Colon Cancer SW480 Cells by Regulation of Akt/NF-ĸB Signaling Pathway. Probiotics and Antimicrobial Proteins, 12, 311-319. [Google Scholar] [CrossRef] [PubMed]
[35] Orlando, A., Refolo, M.G., Messa, C., Amati, L., Lavermicocca, P., Guerra, V., et al. (2012) Antiproliferative and Proapoptotic Effects of Viable or Heat-Killedlactobacillus Paracaseiimpc2.1 Andlactobacillus Rhamnosusgg in HGC-27 Gastric and DLD-1 Colon Cell Lines. Nutrition and Cancer, 64, 1103-1111. [Google Scholar] [CrossRef] [PubMed]
[36] DeGruttola, A.K., Low, D., Mizoguchi, A. and Mizoguchi, E. (2016) Current Understanding of Dysbiosis in Disease in Human and Animal Models. Inflammatory Bowel Diseases, 22, 1137-1150. [Google Scholar] [CrossRef] [PubMed]
[37] Bibiloni, R., Fedorak, R.N., Tannock, G.W., Madsen, K.L., Gionchetti, P., Campieri, M., et al. (2005) VSL#3 Probiotic-Mixture Induces Remission in Patients with Active Ulcerative Colitis. The American Journal of Gastroenterology, 100, 1539-1546. [Google Scholar] [CrossRef] [PubMed]

为你推荐